- Home
- FENC vs CRBP Comparison
FENC vs CRBP Comparison
Compare FENC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- CRBP
- Stock Information
- Founded
- FENC 1996
- CRBP 2009
- Country
- FENC United States
- CRBP United States
- Employees
- FENC N/A
- CRBP N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- CRBP Health Care
- Exchange
- FENC Nasdaq
- CRBP Nasdaq
- Market Cap
- FENC 156.9M
- CRBP 103.6M
- IPO Year
- FENC 2001
- CRBP N/A
- Fundamental
- Price
- FENC $6.49
- CRBP $6.48
- Analyst Decision
- FENC Strong Buy
- CRBP Strong Buy
- Analyst Count
- FENC 2
- CRBP 10
- Target Price
- FENC $14.00
- CRBP $60.89
- AVG Volume (30 Days)
- FENC 55.8K
- CRBP 282.2K
- Earning Date
- FENC 03-10-2025
- CRBP 03-11-2025
- Dividend Yield
- FENC N/A
- CRBP N/A
- EPS Growth
- FENC N/A
- CRBP N/A
- EPS
- FENC N/A
- CRBP N/A
- Revenue
- FENC $47,538,000.00
- CRBP N/A
- Revenue This Year
- FENC $28.99
- CRBP N/A
- Revenue Next Year
- FENC $63.21
- CRBP $270.01
- P/E Ratio
- FENC N/A
- CRBP N/A
- Revenue Growth
- FENC 123.69
- CRBP N/A
- 52 Week Low
- FENC $3.96
- CRBP $6.54
- 52 Week High
- FENC $11.49
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- FENC 47.98
- CRBP 33.08
- Support Level
- FENC $5.75
- CRBP $6.55
- Resistance Level
- FENC $7.06
- CRBP $7.23
- Average True Range (ATR)
- FENC 0.33
- CRBP 0.42
- MACD
- FENC -0.07
- CRBP 0.11
- Stochastic Oscillator
- FENC 57.25
- CRBP 23.67
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.